Who are continue the PI/r-containing HAART.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Triple therapy with ritonavir, Riv, lopinavir/ritonavir (LPV/r), LPV, TMC435, Tipranavir/Ritonavir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/continue-the-pi-r-containing-haart.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

continue the PI/r-containing HAART. — Competitive Intelligence Brief

continue the PI/r-containing HAART. (continue the PI/r-containing HAART.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Infectious disease.

phase 3 Protease inhibitor HIV-1 protease Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

continue the PI/r-containing HAART. (continue the PI/r-containing HAART.) — ASST Fatebenefratelli Sacco. Ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
continue the PI/r-containing HAART. TARGET	continue the PI/r-containing HAART.	ASST Fatebenefratelli Sacco	phase 3	Protease inhibitor	HIV-1 protease
Triple therapy with ritonavir	Triple therapy with ritonavir	Sociedad Andaluza de Enfermedades Infecciosas	marketed	HIV protease inhibitor	HIV-1 protease
Riv	riv	Pfizer	marketed	Protease Inhibitors	HIV-1 protease
lopinavir/ritonavir (LPV/r)	lopinavir/ritonavir (LPV/r)	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Protease inhibitor	HIV-1 protease
LPV	LPV	Bristol-Myers Squibb	phase 3	HIV protease inhibitor	HIV-1 protease
TMC435	TMC435	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
Tipranavir/Ritonavir	Tipranavir/Ritonavir	Johns Hopkins University	phase 3	Protease inhibitor	HIV-1 protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor class)

Pfizer · 4 drugs in this class
French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class
Christopher J. McLeod · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Janssen R&D Ireland · 1 drug in this class
Janssen-Cilag International NV · 1 drug in this class
Johns Hopkins University · 1 drug in this class
Medical Research Council · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). continue the PI/r-containing HAART. — Competitive Intelligence Brief. https://druglandscape.com/ci/continue-the-pi-r-containing-haart. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab